Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CI stock price vs G: inconclusive — current versus $249.01 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at G's multiple
Implied fair value · at CI's multiple
Needs CI P/E.
Snapshot Sep 11, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 79% equity / 21% debt · EV / Revenue 1.30x · EV proxy / EBITDA proxy 7.80x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The Cigna Group · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Genpact Limited · implied price per share
Bear
$38.13
Base
$45.21
Bull
$54.42
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UNITEDHEALTH GROUP INC
CI vs UNH
CVS HEALTH Corp
CI vs CVS
HUMANA INC
CI vs HUM
CENTENE CORP
CI vs CNC
WEST PHARMACEUTICAL SERVICES INC
CI vs WST
BAXTER INTERNATIONAL INC
CI vs BAX
Accenture plc
CI vs ACN
COGNIZANT TECHNOLOGY SOLUTIONS CORP
CI vs CTSH
INTERNATIONAL BUSINESS MACHINES CORP
CI vs IBM
DXC Technology Co
CI vs DXC
EPAM Systems, Inc.
CI vs EPAM
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CI can sustain double-digit revenue growth while improving margins toward G levels, then hold or add on weakness because the current 7.3% implied downside may understate longer-term earnings power; if not, the lower-margin profile and higher net leverage argue for caution.
On a P/E basis, CI’s implied price of $255.18 is 7.3% below its current price of $275.25, suggesting modest downside rather than a clear value gap. The valuation signal is tempered by the fact that CI also trades near the middle-upper part of its historical band, which limits the case for a large rerating.
Supporting Metrics
